{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-002547","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.895388+00:00","generated_at":"2026-06-20T00:37:00.581683+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mesa Labs Q3 revenue -1% to $54.3M; core organic growth 4.6%; net income up 122%","bullets":["Revenues $54,287K, down 1% YoY; organic revenue decline 2.1% due to currency and other headwinds.","Net income $451K ($0.08 diluted EPS) vs $203K in prior year; increase of 122%.","Non-GAAP AOI excluding unusual items $12,856K (24% of revenue), down 7% YoY.","Clinical Genomics revenues $15,585K, down 10% organic; core organic growth 3.3% ex-Sema4 would be 19%.","SDC core organic growth 21.1%; Calibration Solutions impacted by supply chain constraints."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-002547","json":"https://secwatch.observer/filing/0001437749-23-002547.json","markdown":"https://secwatch.observer/filing/0001437749-23-002547.md","text":"https://secwatch.observer/filing/0001437749-23-002547.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774923002547/0001437749-23-002547-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774923002547/mlab20230203_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:37:00.581683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2d912f6ebb08a9f384a92f765e187f67385dca2","claim":"MESA LABORATORIES INC /CO/ reported three and nine months ended December 31, 2022 results: revenue $54,287, net income $451, EPS $0.08 per diluted share.","evidence_excerpt":"3 was 4.6% ● Operating income increased 235% ● Non-GAAP adjusted operating income 1 excluding unusual items decreased 7% Executive Commentary (amounts in thousands) “Revenues of $54,287 in the quarter resulted in an organic revenues decline of 2.1% for the quarter, heavily influenced by currency headwinds across the company, as well as COVID headwinds and the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/724004/000143774923002547/0001437749-23-002547-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended December 31, 2022"},{"label":"Revenue","value":"$54,287"},{"label":"Net income","value":"$451"},{"label":"EPS","value":"$0.08 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}